Welcome to our dedicated page for DURECT SEC filings (Ticker: DRRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Finding the trial data that could shift DURECT’s valuation shouldn’t feel like combing through a lab notebook. Biotech SEC filings are dense—hundreds of pages of clinical results, licensing clauses, and risk factors. DURECT Corporation’s 10-K alone details epigenetic therapy science, cash burn projections, and FDA designations that move the stock.
Stock Titan turns that complexity into clarity. Our AI delivers DURECT SEC filings explained simply—from the DURECT annual report 10-K simplified to every DURECT quarterly earnings report 10-Q filing. Need real-time alerts? We stream DURECT Form 4 insider transactions real-time so you can spot confidence buys or option exercises before the market reacts. Each document arrives with an AI-powered summary, key-metric extractions, and plain-language answers to questions like “What does the latest 8-K say about the AHFIRM trial?”
Here’s what you can unlock:
- Pipeline progress and cash-runway analysis inside 10-Qs—perfect for DURECT earnings report filing analysis
- DURECT insider trading Form 4 transactions mapped against clinical milestones to monitor sentiment
- Instant explanations of any DURECT 8-K material events explained—from FDA feedback to licensing deals
- Compensation metrics in the DURECT proxy statement executive compensation section, tied to trial success hurdles
Whether you’re understanding DURECT SEC documents with AI for the first time or scanning DURECT executive stock transactions Form 4 before earnings, Stock Titan provides complete coverage and professional insight—no PDF diving required.
Durect Corporation filed an S-8 registration statement listing numerous prior S-8 filings and registrations of common stock for employee plans spanning 2000 through 2024. The filing enumerates specific share amounts reserved under various plans (including Employee Stock Purchase Plans, Stock Plans, Directors' Stock Option Plan and legacy plans) and notes a 1-for-10 reverse stock split effected December 5, 2022, with several later registrations stated as ‘‘after giving effect’’ to that split.
Durect Corporation filed an S-8 post-effective amendment that lists prior registration statements and the number of common shares registered for various employee plans dating from 2000 through November 14, 2024. The filing documents multiple past registrations under the 1998 Incentive Stock Plan, the 2000 Employee Stock Purchase Plan and the 2000 Stock Plan (and related director/legacy plans), and notes a 1-for-10 reverse stock split effected December 5, 2022. The document also identifies the company as incorporated in Delaware and includes an EIN and signature by the CFO, Timothy M. Papp.
Durect Corporation (DRRX) filed an S-8 post-effective amendment listing prior S-8 registration statements and the number of shares reserved under various employee equity plans over time. The filing documents multiple historical registrations dating from October 5, 2000 through November 14, 2024, including registrations under the 1998 Incentive Stock Plan, the 2000 Employee Stock Purchase Plan, the 2000 Stock Plan and director/legacy plans. The filing also notes a 1-for-10 reverse stock split effective December 5, 2022.
Durect Corporation (DRRX) filed an S-8 post-effective amendment listing prior S-8 registration statements and the amounts of common stock registered under various employee plans over time. The filing documents multiple historical registrations (ranging from tens of thousands to millions of shares) for stock option plans and employee stock purchase plans, notes a 1-for-10 reverse stock split effective December 5, 2022, and is signed by the CFO.
FAQ
What is the current stock price of DURECT (DRRX)?
What is the market cap of DURECT (DRRX)?
